Key Patient Considerations for the Utilization of Intravenous and Subcutaneous Therapies : Episode 6
Future Predictions for Intravenous and Subcutaneous Biologics
An expert in the field of rheumatology predicts how the treatment landscape will evolve for intravenous and subcutaneous therapies.
Video content above is prompted by the following questions:
- How has the introduction of IV biosimilars impacted your treatment decisions? Do you see a role for subcutaneous biosimilars in the future?
- Do you foresee IV and subcutaneous route of administration always having a role moving forward? How do you see the treatment landscape changing?
Recent Videos
Related Content
K-Cast Written Summary. Key Patient Considerations for Use of Intravenous and Subcutaneous Therapies
October 7th 2024Article
Jill Zouzoulas, M.D., of Tryon Medical Partners in Charlotte, North Carolina, and Jennifer Seminerio, M.D., of University of Southern Florida Health in Tampa, Florida, discussed the biologics and the pros and cons of the intravenous and subcutaneous delivery methods in Managed Healthcare Executive’s K-Cast video series.
Read More
